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Abstract  
Objective: To synthesize cost and health outcomes for current treatment pathways for 
esophageal adenocarcinoma and high grade dysplasia, and model comparative net clinical 
and economic benefits of alternative management scenarios. 
Methods: A decision-analytic model of real-world practices for esophageal adenocarcinoma 
treatment by tumor stage was constructed and validated.  The model synthesized treatment 
probabilities, survival, quality-of-life and resource use extracted from epidemiological 
datasets, published literature and expert opinion. Comparative analyses between current 
practice and five hypothetical scenarios for modified treatment were undertaken.  
Results: Over five years, outcomes across T stage ranged from 4.06 quality-adjusted life-
years and costs of $3,179 for high grade dysplasia, to 1.62 and $50,226 for stage T4.  Greater 
use of endoscopic mucosal resection for stage T1 and measures to reduce esophagectomy 
mortality to 0-3% produced modest gains whereas a 20% reduction in the proportion of 
patients presenting at stage T3 produced large incremental net benefits of $4,971 (95% 
interval: $1,560, $8,368).  
Conclusion:  These findings support measures that promote earlier diagnosis, such as 
developing risk assessment processes or endoscopic surveillance of Barrett’s esophagus.  
Incremental net monetary benefits for other strategies are relatively small in comparison to 
predicted gains from early detection strategies. 
 
Key words: adenocarcinoma of the esophagus, endoscopic mucosal resection, decision-
analytic model 
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Introduction 
Esophagectomy is currently the standard surgical treatment for esophageal adenocarcinoma. 
However, only 25-35% of patients presenting with this disease actually undergo surgery, 
either due to metastatic disease, or comorbidities. New endoscopic techniques such as 
endoscopic mucosal resection (EMR) offer a new approach for early stage disease. EMR can 
be used to assess the depth of tumor invasion, and in some cases it is definitive treatment. 
Further, the combination of EMR and radiofrequency ablation (RFA) is emerging as an 
option for more diffuse intra-mucosal disease[1]
,
[2-4].  
 
Few studies have assessed the cost-effectiveness of treatments for esophageal cancer and high 
grade dysplasia. Pohl et al. 2009 assessed the cost-effectiveness of combination EMR/RFA in 
patients with stage T1a esophageal adenocarcinoma, and suggested that RFA was cost-
effective over a 5-year time frame[1].  Similarly, a UK study by Boger et al. 2010 compared 
first-line RFA (with esophagectomy for subsequent recurrence/progression) versus 
esophagectomy in patients with high grade dysplasia, and although modeling was limited to 
two years follow-up, they concluded that RFA was a cost-effective option.   
 
Studies have produced mixed results for benefits for early cancer detection in Barrett’s 
esophagus surveillance programs[5].  To date, there is a lack of evidence on crucial data 
estimates (e.g., quality of life, proportion of patients progressing from low- to high-grade 
dysplasia), and analyses have not adequately scrutinized the clinical uncertainty of alternative 
management options[5]. Compared with other gastrointestinal cancers, there is limited 
evidence about the cost and health impact of new or modified strategies for controlling 
esophageal adenocarcinoma. These include substituting esophagectomy with endoscopic 
therapies (EMR/RFA), or chemoradiotherapy, concentrating surgical work to high-volume 
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centers, and early testing of tumor response during neoadjuvant chemotherapy by PET scan 
with subsequent targeted care.  
 
To address questions of cost-effectiveness, it is necessary to understand the baseline health 
resource use and outcomes for treating esophageal adenocarcinoma or high grade dysplasia in 
a way that reflects real-world practice [6].  An overview of the major practice patterns, 
natural history and management of esophageal cancer and the associated health care 
resources used in a large Australian patient cohort (n=1100) has been reported recently [6]. 
To better evaluate the current range of treatment options, we examined treatment pathways 
and outcomes for esophageal adenocarcinoma, as well as Barrett’s esophagus with high grade 
dysplasia.  Patient survival, health-related quality of life and associated events, resource use 
from associated treatments, and cost were estimated for current management pathways, and a 
decision-analytic health economic model was developed. Alternative hypothetical 
management scenarios were then compared to current pathways to estimate potential benefits 
for alternative scenarios and management strategies.   
 
Materials and Methods 
 
Model structure 
A decision-analytic model was constructed in TreeAge Pro 2011 software (TreeAge Software 
Inc, Williamstown, MA, USA) (Figures 1a and 1b).  This model explicitly identified the 
sequence and linkage of the major treatment pathways for different stages (T1-4) of 
esophageal adenocarcinoma, and also for high-grade dysplasia (HGD) in Barrett’s esophagus, 
and tracked cohorts of patients with these diagnoses. To allow the majority of resource use 
and survival outcomes to accrue, the time horizon extended to five years after diagnosis. To 
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ensure that the model reproduced real-world practice, the medical pathways were identified 
and independently confirmed by five specialist upper gastrointestinal surgeons who were all 
actively engaged in esophageal cancer management.  Several iterations of the model were 
constructed before the model was finalized, with consensus reached when it was necessary to 
balance treatment complexity with data availability.  
 
The model pathways were first divided into T stages (i.e., American Joint Committee for 
Cancer tumor stages T1 to T4) at diagnosis, and separate pathways were also constructed for 
patients with distant metastases, and patients presenting with HGD. Pathways for stages T2 to 
T4 were structurally identical, with patients receiving either non-surgical treatment or 
surgical treatment, with or without neoadjuvant therapies (Figure 1b), although the 
probabilities of different outcomes differed according to clinical stage.  Those undergoing 
surgical treatment (with or without neoadjuvant therapy) followed paths where they either 
died peri-operatively, died after tumor recurrence with distant metastases, died after a period 
of time from unrelated causes, or remained alive with no tumor recurrence at five years. 
Pathways for T1 stage and HGD were more complex (Figure 1a), and also included 
endoscopic ablation of Barrett’s esophagus and endoscopic mucosal resection options, either 
alone or prior to tumor recurrence and subsequent esophagectomy.  The model allocated 
patients to stages and associated treatment pathways according to mutually exclusive 
probabilities (Table 1).  Health outcomes and costs were assigned to the terminal node of 
each pathway and values were calculated for each course of action along the decision tree[7]. 
 
Data sources 
The main types of data in the model were treatment probabilities, survival (years), utilities 
(i.e., preference-based health-related quality of life) and medical costs.  Data used to populate 
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the model were based where feasible on the Australian Cancer Study Clinical Follow Up 
(ACS), a ‘patterns of care’ study which included 795 patients with esophageal 
adenocarcinoma or gastro-esophageal junction adenocarcinomas. These patients were 
recruited between 2002-2008, had a mean age of 62 years, 61% were men, predominantly 
Caucasian, and 25% were current smokers[8].  ACS data were supplemented with data from 
prospectively collected datasets stored in databases and maintained by the major esophageal 
cancer units in Adelaide and Brisbane, Australia. These data sets contained outcome data 
from more than 2000 individuals with esophageal cancer, and more than 1000 patients who 
had undergone an esophagectomy.  Other treatment probabilities were determined from 
review of published literature and Australian all-cause mortality data (Table 1).  Odds ratios 
were applied to baseline risk to consistently model treatment effects on absolute incremental 
survival[9] .   
 
As the ACS included only patients with invasive esophageal adenocarcinoma, we reviewed 
the literature (see Appendix 1 for search terms) to obtain treatment estimates for patients 
presenting with high-grade dysplasia, and then checked these data for consistency against the 
prospective database maintained in Adelaide, South Australia.  Remaining gaps in evidence 
to populate the decision tree were derived from consensus views of the five surgeons (expert 
opinion) (see Appendix 2).   
 
Costs of treatment were calculated from patient-level resource data collected by the ACS 
over several years via medical chart review[6]. Prices applied to resource use were taken 
from national price schedules and public hospital clinical costings for inpatient surgical stays. 
The mean cost of an esophagectomy included in-hospital adverse events, and intensive care 
unit admissions for some patients[6].  Statistical analyses of costs allowed for their skewed 
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nature [10]. Australian life-tables provided information on background all-cause 
mortality[11]. Utility scores to adjust survival estimates in estimating quality-adjusted life 
years were obtained from a literature review on utility weights for treatments for esophageal 
adenocarcinoma[12-15]. Table 1 lists all data estimates and tabled data in the model with 
their respective sources and ranges tested in sensitivity analyses (see below).  In addition, 
based on ACS and Adelaide datasets, treatment probabilities for neoadjuvant therapy plus 
surgery across tumor stages ranged from 0.62 (T2) to 0.81 (T4), 0.71 to 0.77 for surgery 
without neoadjuvant therapy, 0.02 to 0.06 for peri-operative deaths, 0.19 to 0.42 for being 
alive at five years following surgical treatment, and 0.26 to 0.48 for being alive at five years 
following neoadjuvant with surgical therapy.  
 
Analyses 
Using a natural history model with current practice, we estimated the economic outcomes for 
treatment options connected with actual patterns of care for managing patients with a 
diagnosis of HGD or esophageal adenocarcinoma.  Our analysis took an Australian health 
system perspective when measuring and valuing health care resources. Costs were valued in 
2009 Australian dollars and converted to 2009 US dollars using a purchasing power parity of 
1 AUD = 1.553 USD[16].  All dollars presented here are USD ($). Further details on the 
resource quantities and medical costs have been published previously[17]. Costs and quality-
adjusted life years were discounted at 5% annually.  The costs and effects of current practice 
were compared with the hypothetical scenarios described in Table 2 and incremental net 
monetary benefit (net benefit) generated. For comparing the current treatment with each 
hypothetical scenario separately, incremental net benefit was calculated over a 5-year period 
as: 
Incremental net benefit= λ × ∆E−∆C 
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where λ= $50,000 was the base case threshold value applied to incremental quality-adjusted 
life-years gained (∆E) and ΔC is the incremental cost. A decision-making threshold of 
$50,000 was used.  The strategy with the highest positive incremental net benefit (hereafter 
called ‘net benefit’) is the preferred option, whereas a negative net benefit indicates a net loss 
and such a strategy should not be adopted.   
 
Sensitivity analyses 
Probabilistic sensitivity analyses on net benefit were undertaken to examine the joint 
variation possible within the data point estimates used in the model, based on their known 
distributions. Beta distributions assigned to treatment probabilities, Dirichlet distributions for 
dependent variables (e.g., proportions in each T stage), log normal distributions to survival 
estimates and gamma distributions to cost variables because costs were right-skewed[6] 
(Table 1). Where patient-level data were used (e.g., from the ACS) the distributions assigned 
were based on means, standard deviations and medians, where appropriate. The analyses 
were conducted by re-sampling from the nominated parameter distributions across 5,000 
iterations (Monte Carlo simulation). Simulated mean net benefits with 95% uncertainty 
intervals (95%UI) were generated to estimate the extent of uncertainty for each comparison.  
 
Alternative management scenarios 
To evaluate the impact of changing clinical practice and outcomes, five hypothetical 
scenarios were tested. These involved changing current therapy by:  
(1) Altering the proportion of patients with stage T1 adenocarcinoma undergoing 
endoscopic mucosal resection;  
(2) Modifying peri-operative mortality rates for esophagectomy;  
(3) Increasing the proportion of patients diagnosed at earlier stages;  
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(4) In patients undergoing neoadjuvant chemotherapy, adding fluorodeoxyglucose 
positron emission tomography after the first cycle of chemotherapy to assess tumor 
response, and modify treatment to progress directly to surgery if poor response; and  
(5) Increasing the proportion of patients undergoing definitive chemoradiotherapy as 
first-line therapy.   
Full details and the rationale behind each of the five scenarios are given in Table 2. 
 
Results 
Over five years, the total medical cost for treating an individual with esophageal 
adenocarcinoma varied between $33,572 and $50,226, depending on T stage (Table 3).  Costs 
were $8,267 for patients with distant metastases. Over five years, survival ranged from 0.97 
to 4.66 years with a mean 2.5 years for T stages T2 and T3.  Patients with HGD incurred 
fewer costs ($23,179) than patients with invasive adenocarcinoma, and had a mean survival 
of 4.6 years over five years of follow up.  Overall, current treatment patterns for HGD and 
adenocarcinoma of the esophagus had mean quality-adjusted life years of 2.25 and mean 
costs of $41,345 over five years (Table 3).   
 
Compared with current treatment costs and outcomes for HGD and esophageal 
adenocarcinoma, the greatest additional net benefit per patient among the five scenarios of 
interest was observed for potentially down-staging T3 tumors through earlier detection (Table 
4). The incremental net benefit was $4971 (95%UI: $1560, $8368) for  a 20% reduction in 
the proportion of patients presenting with stage T3 disease, redistributed equally to T2, T1 
and HGD (Table 4), corresponding to modest gains from a hypothetical early detection 
process. Net benefits were relatively modest but positive (cost-effective) for a peri-operative 
mortality rate of 1% (net benefit $233, 95%UI: -$297, $95), increased use of EMR treatment 
in patients with T1 stage adenocarcinoma (e.g., 100% T1a + 25% T1b: net benefit $428, 
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95%UI: $182, $726) and adding fluorodeoxyglucose positron emission tomography for 
assessing response to neoadjuvant therapy (net benefit $805, 95%UI: $59, $1596), and 
increasing the use of chemoradiotherapy in T2 and T3 by 25% (net benefit $2660, 95%UI: -
$1716, $9712)(Table 4). Net benefits were positive but inconclusive for the use of 
chemoradiotherapy as definitive treatment for T2 and T3 cancers (replacing esophagectomy 
as definitive treatment) indicated by the 95% limits spanning across expected net loss to net 
benefit (Table 4). 
 
Discussion 
Cost-effectiveness analysis is the process of systematically comparing the relative health care 
costs and benefits of alternative strategies to inform decision-makers of the strategy or 
treatment pathways with highest net benefit [18], as well as those likely to provide better 
value if implemented more widely, and areas which might benefit from further research [19-
21]. Systematic assessment of incremental costs and effects requires consideration of natural 
history and interaction with practice, and this is particularly important for conditions such as 
esophageal adenocarcinoma which has multiple strategies and pathways for monitoring, 
diagnosis and management, all conditional on the stage of disease at presentation[22]. While 
costs might be of secondary concern to clinicians who primarily seek to optimize outcomes 
for individual patients, ultimately, resource allocation decisions do affect everyday clinical 
care in settings with budgetary pressures [23]. It is mandatory for regulatory bodies in 
Canada, UK, Australia and most of the Western world to evaluate cost-effectiveness of new 
technologies when considering potential government reimbursement. 
 
Our results suggest that compared with current practice, potential incremental net benefit, at a 
threshold value of $50,000 per quality-adjusted life year, is greatest for early detection in the 
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context of a Barrett’s esophagus surveillance program which shifts the proportion of patients 
presenting with stage T3 cancer to earlier stages (e.g., $4971 with 20% down shift in T3).  
This is due to this strategy having a marked impact on both increased survival prospects and 
lower costs associated with treatment pathways for patients with stage T1 adenocarcinoma or 
HGD. However, the cost to implement early detection strategies (e.g., surveillance, detection 
through biomarker screening) is not included in the net benefit results, and will have the 
impact of lowering this net benefit. Further modeling will be required to evaluate this further, 
and our model suggests that the cost of early detection strategies which down stage 20% of 
individuals with T3 stage to HGD or T1, must not exceed $4971 per patient within the early 
detection program for it to be a worthwhile health care investment.    
 
Since there are currently only a small proportion of patients presenting with stage T1 
adenocarcinoma (15.2%) or HGD (2.2%) relative to stage T2-T4 adenocarcinoma, the 
economic impact of strategies which only improve the outcome for early stages, but not 
increase the proportion presenting with early stage disease, is likely to be quite modest when 
evaluated in the context of the overall population. On the other hand strategies that increase 
the proportion with early stage disease, by shifting people from late stage to early stage might 
be more promising, and do not depend on the development of new technologies or devices.  
This was shown in our findings when, for example, where hypothetically an increased 
proportion of patients with stage T1 adenocarcinoma underwent EMR rather than 
esophagectomy produced a net benefit of only $428, a much smaller gain than for early 
detection strategies.  Despite this, our results support the use of EMR for T1 tumor treatment 
as shown by the positive net benefit. This result is also consistent with previous health 
economic reports of endoscopic techniques as preferred treatments for HGD and stage T1 
adenocarcinoma versus esophagectomy [24-25].   
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Utility scores following esophagectomy over the longer-term and the cost for esophagectomy 
were critical parameters in our natural history model. The high cost of the hospital episode 
for esophagectomy is also reflected in the analyses. Surgical treatment is complex, and it is 
common for adverse events to occur, resulting in lengthy hospital stays and longer recovery 
periods in some patients. Previous work on patient-level resource data, that formed the basis 
of the cost estimates modeled here, showed that that 24% of the patients undergoing 
esophagectomy experienced at least one significant complication and the mean length of stay 
for the surgical episode was 15.5 days [6].  Many of the patients undergoing esophagectomy 
were hospitalized for a much longer period of time [6], whereas radiofrequency ablation and 
EMR are typically same-day procedures. However, these endoscopic procedures usually 
require several procedures per patient to complete a course of treatment [1].  In assessing the 
subset of patients specifically with stage T1 adenocarcinoma or HGD, our results suggest that 
some economic efficiency might be gained from treatment pathways which involve less-
invasive endoscopic therapies. This is driven by reduced treatment related morbidity and 
mortality and lower costs compared to surgery.  
 
In our study, hypothetically modelling different mortality rates for esophagectomy yielded 
different outcomes. When mortality rates were 5% or 10% there was no net benefit for the 
use of esophagectomy, although there was a benefit for mortality rates of 0%, 1% and 3%. 
This suggests that the perioperative rate for esophagectomy has a critical impact on whether 
or not this procedure is clinical effective and cost effective in patients with early stage 
disease, and it is likely that perioperative mortality rates of no more than 3% are required for 
esophagectomy to be an appropriate procedure for the treatment of these patients.  
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Mortality associated with esophagectomy has progressively declined over recent decades. A 
review of esophagectomy outcomes for the 1990’s showed a 8.8% in hospital mortality rate 
for this decade[26], although lower mortality (<5.0%) was observed in high volume centres 
[27]. More recent reports from the 2000’s describe mortality rates of 3-5%, again with lower 
mortality rates consistently reported from high volume centres [28]. A study from our centres 
described an in hospital mortality rate for esophagectomy in five Australian hospitals of 
3.5%[29]. A lower mortality rate of 1.2% has been reported for esophagectomy in patients 
specifically presenting with stage T1 adenocarcinoma or HGD[30]. Our current study 
supports surgical treatment for early stage esophageal cancer only in centres which can 
consistently achieve mortality rates for esophagectomy of 3% or less for patients with this 
disease stage. 
 
Our study has a number of limitations.  Despite the use of large Australian-based datasets, 
which reflect recent health care utilization and the natural history of esophageal 
adenocarcinoma, a number of gaps remained for uncommon pathway probabilities and it was 
necessary to depend on published reports or even clinical judgment for some of these. In part 
this occurred because ablation therapies are relatively new. The esophageal surgeons 
contributing to the development of this model all worked in high volume hospitals, and some 
also had personal experience with endoscopic ablative therapies. Whilst using “expert 
opinion” may have introduced some bias, this was counteracted by testing across a 
distribution of plausible values to address the potential uncertainty.  Finally, utility scores, 
similar to health-related quality of life assessments, from Australian patients were unavailable 
and therefore we relied on those reported in the literature for US and European populations.  
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The implications of our modeling lend support to measures that promote earlier presentation 
of tumors, such as developing risk factor assessment processes and endoscopic surveillance 
of Barrett’s esophagus.  This has been a particularly contentious topic with health economic 
studies producing mixed results as to the cost-effectiveness of endoscopic surveillance of 
Barrett’s esophagus [5]. In 2009 two US studies recorded mean costs per patient under 
surveillance of $2,769[31] and $11,532[32] for surveillance programs involving 5-yearly 
screening intervals, and $7,940  was reported for one UK study with 3-yearly intervals 
(converted to $ 2009)[13]. Our cost cut-off of $4971 per patient within an early detection 
program appears to be in the overall range of these costs. However, research is still needed to 
explicitly model the long-term economic impact of surveillance of Barrett’s esophagus, and 
this should incorporate natural history models for current treatment, intervention resources, 
screening intervals and adverse events.  
 
There is widespread interest in improving health outcomes for patients with esophageal 
adenocarcinoma and in particular, diagnosing this disease at an earlier stage, so that less 
invasive endoscopic options such as mucosal ablation and endoscopic mucosal resection can 
be applied. The majority of patients currently present with stage T2-T4 tumors, and only a 
minority present with early cancer or HGD.  Consequently, to improve outcomes the most 
promising cost-effective approach might be early detection to avoid esophagectomy, 
chemotherapy and radiotherapy.  Our data suggest that this requires down-staging of at least 
20% of T3 tumors to stage T1 or HGD, at a cost of less than $4971 per patient under 
surveillance.  
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Appendix 1.  Literature search terms for model probabilities  
Database: PubMED, MEDLINE 
For EMR (split between T1m T1sm) data: 
 (esophagus OR oesophagus) AND dysplasia AND (T1a OR T1s OR T1b or T1sm) 
8 results. References from selected papers to be searched. 
 
For ablation findings: 
 (esophagus OR oesophagus) AND (radiofrequency OR RFA) AND ablation AND (dysplasia 
OR HGD) 
24 results. References from selected papers to be searched. 
 
For surgical and endoscopic therapy survival or other data: 
(esophagus OR oesophagus) AND (T1a OR T1s OR T1b or T1sm) AND (survival OR 
mortality) 
12 results. References from selected papers to be searched. 
 
Appendix 2. Method to elicit expert opinion for some data estimates 
Independent interviews were undertaken between authors LG and NG and five esophageal 
surgeons.  The interviews were designed to ask the same set of questions where gaps existed 
in the literature.  Responses were recorded and the range of all responses collated.  Consensus 
was reached via email correspondence after the surgeons were given the opportunity to 
agree/disagree with the group range.  An average was taken of each estimate for the baseline 
model and range included in the sensitivity analyses. The surgeons were chosen from high-
volume centres and with an active interest in esophageal cancer research.  The locations 
spanned two Australian states and surgeons worked in private and public hospital settings. 
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Table 1. Model data estimates with their distributions and sources.  
Description Base estimate (SD) Distribution Source 
Costs (Mean AU$)    
Esophagectomy
1
 51,565 (36,749) Gamma (α= 1.9689, λ<0.0001) ACS
2
 
Neo chemorad 25,732 (34,693) Gamma (α= 0.5501, λ<0.0001) ACS 
Radiotherapy for pts treated surgically 5,782 (3,339) Gamma (α= 2.9986, λ=0.0005) ACS 
Endoscopic mucosal resection (5 yrs) 12,134 Gamma (α=11.1123, λ=0.0009) Ade
3 
Ablation (5 yrs) 17,419 Gamma (α= 11.1098, λ=0.0006) Ade 
Diagnostic tests for esophageal 
adenocarcinoma 
2,338 (749) Gamma (α=9.7437, λ=0.0042) ACS 
Follow-up in surgically treated pts 6,433 (4,059) Gamma (α=2.5126, λ=0.0004) ACS 
Follow-up in non-surgically treated pts 11,524 (5,762) Gamma (α=4.0003, λ=0.0004) ACS 
Palliative chemorad and stenting 10,500 Gamma (α=11.1111, λ=0.0011) Ade 
Definitive chemorad for pts not treated 
surgically 
17,900 Gamma (α= 1.1111, λ=0.0006) ACS 
Definitive chemorad for pts treated 
surgically
4
 
3,500 Gamma (α= 11.1111, λ=0.0032) ACS 
Probabilties
5 
   
Pts in each T stage (T1-T4, DM) 0.022, 0.152, 0.228, 
0.431, 0.052, 0.115 
Dirichlet (25; 170; 255; 
482; 58; 129) 
ACS/  
Ade
6 
Treatment for HGD (EMR, Ablation, no 
treatment) 
0.85, 0.08, 0.07 Dirichlet (85, 8, 7) Expert 
Treatment for T1 (esophagectomy, EMR, 
Radiation, no treatment) 
0.43, 0.47, 0.05, 0.05 Dirichlet (43, 47, 5, 5) Expert 
Recurrence after ablation for T1a/HGD 0.036 Beta (n=303, r=11) Shaheen& 
Prasad 
Recurrence after ablation has DM 0.182 Beta (n=11, r=2) “ 
Alive
7
 if HGD pt receives no treatment 0.600 Beta (n=100, r=60) Expert 
EMR of T1 will detect a T1a 0.784 Beta (α=9.6, β=2.6) Peters 
2005 & 
2008 
T1a receives ablation 0.400 Beta (n=100, r=40) Expert 
T1b pt eligible and receiving surgery 0.700 Beta (n=100, r=70) Expert 
Local recurrence after ablation receiving 
EMR 
0.330 Beta (α=29.8, β=60.5) Expert 
Alive for recurrent local T1 receiving 
EMR 
0.800 Beta (n=100, r=80) Expert 
T1b not receiving surgery will get 
radiation 
0.722 Beta (n=18, r=13) ACS 
Alive for T1 receiving radiation only 0.125 Beta (n=32, r=4) 
ACS/Ade 
“ 
“ 
Alive after esophagectomy for T1 
tumour 
0.636 Beta (n=118, r=75) 
T1 death from surgery 0.017 Beta (n=120, r=2) 
Survival (mean, years)    
With DM  0.971 Log normal (μ=-0.234, σ=0.640) ACS 
For those dying peri-operatively  0.500 Beta (α=3.125, β= 3.125) “ 
Survival for T1-2 cases receiving surg 
with neo  
1.805 Log normal (μ=0.590, σ= 0.033) “ 
For T1-T2 not receiving surgery  1.243 Log normal (μ=-0.118, σ=0.819) “ 
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For T3-T4 cases receiving neo  1.622 Log normal (μ=0.347, σ=0.523) “ 
For T3-T4 cases not receiving surgery  1.112 Log normal (μ=-0.170, σ=0.743) “ 
For any T stage receiving surgery  1.753 Log normal (μ=0.401, σ=0.567) “ 
Utilities (HRQoL score 0=poorest, 
1=highest) 
   
Diagnosis of HGD 0.84 Beta (α=7.1111, β=1.3545) [33,15] 
Diagnosis of T1 or T2 0.838 Beta (α=7.2000, β=1.3919) [13] 
Diagnosis of T3 or T4 0.66 Beta (α=15.1111, β=7.7845) [13,33] 
Distant metastases 0.345 Beta (α=29.1111, β=55.2689) [12] 
Successful ablation 0.93 Beta (α=3.1111, β=0.2342) [15] 
Residual metastases/dysplasia after 
ablation 
0.90 Beta (α=4.4444, β=0.4938) [15] 
Immediately following esophagectomy 0.86 Beta (α=6.2222, β=1.0129) [12] 
Long-term utility following 
esophagectomy 
0.92 Beta (α=3.5556, β=0.3092) [12] 
Pts=patients, DM=distant metastases, Neo=neoadjuvant therapy, chemorad=chemoradiotherapy, HRQoL=Health-Related 
Quality of Life, HGD=high grade dysplasia, EMR=endoscopic mucosal resection 
1. Includes the cost of post-operative tests and, for a proportion of patients, complications and subsequent longer hospital stay. 
2. ACS:  patient-level resource data from the Australian Cancer Study Clinical Follow Up [17] 
3. Ade = Adelaide; Based on point estimates from dataset at Flinders Medical Centre and Royal Adelaide Hospital (n=325) 
4. Includes patients who received or did not receive neoadjuvant therapy.  
5. To conserve space, the probabilities for T2 to T4 are not provided in the table and are described in the main text. 
6. Weighted average of Adelaide and ACS CFU datasets. 
7. Alive is assumed to mean alive at 5-years from diagnosis 
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Table 2. Description and rationale of five hypothetical scenarios tested 
Scenario  
Name 
Description Rationale 
EMR Increasing the number of patients with 
stage T1 esophageal adenocarcinoma 
undergoing EMR, rather than 
esophagectomy (proportion of patients 
with T1a increased to 100% and then T1b 
additionally increased by 25%, 50%)  
Growing evidence that EMR may produce 
clinically equivalent outcomes, fewer 
side-effects and quicker recovery 
compared with esophagectomy in 
patients with stage T1a esophageal 
adenocarcinoma. 
Operative Mortality Altering peri-operative mortality rates for 
esophagectomy to  1%, 3%, 5%, 10% 
(applied to all T stages)  
Average rate of 3.7% seen in NSW[34], 
rates differ by high vs. low volume 
hospitals, 1% mortality in patients 
undergoing esophagectomy for 
surveillance detected early stage cancer. 
Downstaging Increasing the numbers of patients 
diagnosed at T2, T1 and HGD stages by 
assuming a proportion of patients with T3 
tumours are absorbed equally across the 
T2, T1 and HGD categories. Proportions 
included 10%, 20%, 30%, 40% 
As more patients with Barrett’s 
esophagus are monitored through 
endoscopy surveillance programs, 
increasing numbers of cancers are 
expected to be detected at earlier T 
stages.  The value of INB here 
corresponds to the maximum per patient 
cost of a cost-effective surveillance 
program with associated level of 
effectiveness  
 
Add PET Adding FDG-PET to T2 and T3 pathways 
after first cycle of neoadjuvant 
chemotherapy to aid identify poor 
responders.  Poor responders then 
discontinue neoadjuvant therapy. 
Assumed 64% responders [35]. 
If FDG-PET is successful in accurately 
differentiating responders vs. non-
responders, therapy can be more 
effectively targeted, and can avoid 
unnecessary neoadjuvant therapy in 
likely non-responders. 
Chemo/radiotherapy Increasing the proportion of patients with 
T2 and T3 stage cancer receiving definitive 
chemoradiotherapy (replacing 
esophagectomy) and receive 
esophagectomy for recurrent cancer. 
Proportions included 25%, 50%, 100% 
Anecdotal evidence that some patients 
respond as well to definitive 
chemoradiotherapy as they do to 
surgery. 
EMR = endoscopic mucosal resection, NSW=New South Wales, RCT=randomized controlled trial, DM=distant metastases, 
Neo=neoadjuvant therapy, chemorad=chemoradiotherapy, QALYs= Quality-Adjusted Life Years, HGD=high grade dysplasia, 
EMR=endoscopic mucosal resection, Chemo=chemotherapy, FDG-PET = fluorodeoxyglucose positron emission tomography
Archived at the Flinders Academic Commons: http://dspace.flinders.edu.au/dspace/ 
20 
 
 
Table 3. Natural history cost, life years and QALYs over 5 year follow up with current 
practice by HGD and cancer T stage (means) 
 
Stage 
Costs 
(USD) 
Life 
years 
QALYs 
HGD 23,179 4.55 4.06 
T1 33,572 4.66 4.26 
T2 50,377 2.53 2.18 
T3 50,001 2.51 2.07 
T4 50,226 2.03 1.62 
Distant metastases 8,267 0.97 0.33 
Total 41,345 2.69 2.25 
HGD = high grade dysplasia, QALYs = quality-adjusted life years
Archived at the Flinders Academic Commons: http://dspace.flinders.edu.au/dspace/ 
21 
 
 
Table 4. Incremental net benefits for specified scenarios in relation to the base case (USD) 
 Base value New value 
 Inc
1
 
Costs $ 
Inc
1
 
QALYs 
Inc net benefit
1
 $ 
(95% UI) 
EMR for T1
2
 
1. 100% T1a 
2. 100% T1a +25% T1b 
3. 100% T1a +50% T1b 
 
T1a 90% 
EMR/Ablat 
T1sm 70% 
Esophag, 
0%EMR/Ablat
 
100% T1a 
100% T1a +25% T1b 
100% T1a +50% T1b 
 
-256 
-357 
-458 
 
-0.001 
0.002 
0.005 
 
228 (43, 477) 
428 (183, 726) 
628 (296, 1018) 
 
Operative Mortality 
1. 0%
3
 
2. 1% 
3. 3% 
4. 5% 
5. 10% 
2% to 6%  
depending on T 
stage 
 
0%
3
 
1% 
3% 
5% 
10% 
225 
166 
8 
-70 
-364 
0.049 
0.036 
0.001 
-0.018 
-0.086 
1367 (798, 2166) 
989 (455, 1726) 
233 (-297, 895) 
-523 (-1133, 113) 
-2413 (-3455, -1593) 
Down staging T3 
1. 10% 
2. 20% 
3. 30% 
4. 40% 
n(T3)=482
4 
n(T3)=434 
n(T3)=386 
n(T3)=337 
n(T3)=289 
-531 
-1065 
-1598 
-2128 
0.061 
0.124 
0.185 
0.248 
2468 (-480, 5497) 
4971 (1560, 8368) 
7490 (3420, 11363) 
9975 (5287, 14243) 
Add PET 
64% respond to neoadj 
chemorad (Total within T2 
and T3)  
$16,569 
Cost chemorad
5
  
(T2)=$14,958 
(T3)=$13,437 
-833 0.000 805 (59, 1596) 
Chemorad 
1. 25% 
2. 50% 
3. 100% 
Esophag 1
st
 line 
n(T2,T3)=196, 
362 
Chemorad 1
st
 line
2
: 
n(T2,T3)=49, 91 
n(T2,T3)=98, 181 
n(T2,T3)=196, 362 
-842 
-1683 
-3366 
0.056 
0.113 
0.226 
2660 (-1716, 9712) 
5323 (-3432, 9424) 
10641 (-6864, 38848) 
      
1. Probabilistic sensitivity analysis using 5000 Monte Carlo simulations. Net monetary benefit at a threshold value of $50,000 per QALYs. UI- uncertainty interval, 2.5% and 97.5% ranked values 
after sorting min to max. Incremental net benefits using current practice (see table 3)  as the reference case for each scenario. 
2. Replaces esophagectomy, outcomes remain the same for esophagectomy 
3. New %peri-op mortality rate applies to all T stages  
4. Dispersion into earlier stages not shown in new value column. Baseline values for numbers of patients are:T3=482, T2=255, T1=170, HGD=25 
5. Based on formula cost(T2)=($25732 +$928)*0.80 + ($8577 + $928)*0.20, cost(T3)= ($25732 +$928)*0.62 + ($8577 + $928)*0.48.  $8577 of chemrad costs is incurred for 2 weeks treatment 
before a response is known/tested for. 
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Figure 1a Illustration of decision-analytic model for T1 and HGD  
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Figure 1b Illustration of decision analytic model for T2-Distant Metastases 
 
NB: Branches T2 and T3 are identical to T4.
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